127
Participants
Start Date
June 30, 2013
Primary Completion Date
April 30, 2014
Study Completion Date
June 30, 2014
SOF
Sofosbuvir (SOF) 400 mg tablet administered orally once daily
RBV
Ribavirin (RBV) tablets administered orally in a divided daily dose using weight-based dosing (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Central Clinical Hospital of the Russian Academy of Sciences, Moscow
Central Scientific and Research Institute of Epidemiology of Rospotrebnadzor, Moscow
Central Scientific Research Institution of Gastroenterology of Moscow Healthcare Department, Moscow
City Clinical Hospital 24, Moscow
Clinical Diagnostics and Research Center of Federal Bedgetary Institution, Moscow
Infectious Clinical Hospital No. 1, Moscow
Institute of Nutrition of Academy of Sciences, Moscow
Institution of Healthcare of Sverdlovsk Region, Moscow
Institution of High Professional Education First Moscow State Medical University, Moscow
Institution of Tumen Region, Moscow
Krasnoyarsk Regional Center for Prevention and Control of AIDS and Infectious Diseases, Moscow
Scientific Research Institution of Emergency Care n.a. N.V. Sclifosovskiy of Moscow, Moscow
Stavropol State Medical University of Ministry of Healthcare, Moscow
Medical Military Academy n.a. S.M. Kirov, Saint Petersburg
Saint-Petersburg Center for Prevention and Control of AIDS and Infectious Diseases, Saint Petersburg
Medical Company Hepatolog, Samara
Lead Sponsor
Gilead Sciences
INDUSTRY